LLY
🚀 Eli Lilly’s Monjaro shows promise in obesity treatment, with an average weight reduction of 26% in patients.
⚠️ The drug is still in phase three clinical trials for specific application in overweight reduction.
📈 Positive evolution of Monjaro has contributed to improved financial results for Eli Lilly.
💰 The company has an impressive history of dividend payments, increasing them consistently for 11 years.
@rankia:
“Eli Lilly is another major player in the pharmaceutical sector, which in recent months has developed Monjaro, a treatment initially conceived for type 2 diabetes, but which has also shown great promise in the fight against obesity. Studies have revealed that Monjaro can lead to an average reduction of 26% in the body weight of patients with obesity, even in those who do not suffer from diabetes. However, although this advance is significant, the drug is still in phase three of clinical trials for the specific application in reducing overweight.”
Watch the exact part of the video where Rankia talks about Eli Lilly here:
View the video on YouTube.
Read more articles featuring the most recent analysis of Eli Lilly (LLY) at this link: LLY stock.
